Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Cormorant Asset Management
AddedFeb 13, 2024
UpdatedJun 28, 2026
Cormorant Asset Management

Cormorant Asset Management

Operating

Cormorant Asset Management: A Boston-based hedge fund sponsor specializing in biotech and life sciences.

Location
Boston, MA, US
Founded
2013
Firm
Compare
Portfolio
Employees

Investments

Synnovation Therapeutics
Synnovation Therapeutics

Total Raised

$139M

Rounds

3

Series A$102MDecember 2023
Supira Medical
Supira Medical

Total Raised

$120.5M

Rounds

4

Series D$40MNovember 2023
Series C$30MFebruary 2022
Vyne Therapeutics
Vyne Therapeutics
Public

Total Raised

$297.8M

Rounds

7

Post Ipo Equity$88MOctober 2023
Triveni Bio
Triveni Bio
Series C

Total Raised

$272M

Rounds

3

Series A$92MOctober 2023
Akura Medical
Akura Medical

Total Raised

$60M

Rounds

2

Series B$35MOctober 2023
Star Therapeutics
Star Therapeutics

Total Raised

$190M

Rounds

2

Series C$90MSeptember 2023
Fore Biotherapeutics
Fore Biotherapeutics

Total Raised

$166.5M

Rounds

9

Series D$75MAugust 2023
Rapport Therapeutics
Rapport Therapeutics

Total Raised

$250M

Rounds

2

Series B$150MAugust 2023
Adarx Pharmaceuticals
Adarx Pharmaceuticals

Total Raised

$332M

Rounds

5

Series C$200MAugust 2023
Nexo Therapeutics
Nexo Therapeutics

Total Raised

$60M

Rounds

1

Series A$60MJuly 2023
Myra Vision
Myra Vision

Total Raised

$50.5M

Rounds

4

Series B$25MJune 2023
OnKure Therapeutics
OnKure Therapeutics
Public

Total Raised

$121.5M

Rounds

8

Series C$54MMay 2023
Bioventrix
Bioventrix

Total Raised

$230.2M

Rounds

14

Series A$48.5MApril 2023
Andera Partners
Andera Partners

Total Raised

$48.5M

Rounds

1

Series A$48.5MApril 2023
Chroma Medicine
Chroma Medicine

Total Raised

$260M

Rounds

3

Series B$135MMarch 2023
Tioga Cardiovascular
Tioga Cardiovascular

Total Raised

$74.6M

Rounds

3

Series C$30MFebruary 2023
Garuda Therapeutics
Garuda Therapeutics

Total Raised

$134M

Rounds

2

Series B$62MFebruary 2023
Ensoma
Ensoma

Total Raised

$205M

Rounds

3

Series B$85MJanuary 2023
Fog Pharmaceuticals
Fog Pharmaceuticals

Total Raised

$385.3M

Rounds

5

Series D$178MNovember 2022
Orionis Biosciences
Orionis Biosciences

Total Raised

$79.5M

Rounds

8

Series C$55MOctober 2022
Atia Vision
Atia Vision

Total Raised

$111.1M

Rounds

8

Series E$42MAugust 2022
Moma Therapeutics
Moma Therapeutics

Total Raised

$236M

Rounds

2

Series B$150MMay 2022
Adona Medical
Adona Medical

Total Raised

$62M

Rounds

3

Series B$37.5MApril 2022
Electra Therapeutics
Electra Therapeutics

Total Raised

$100M

Rounds

2

Series B$84MFebruary 2022